Proteomic Profiling of SGLT-2 Inhibitor Canagliflozin in a Swine Model of Chronic Myocardial Ischemia.
Dwight D HarrisSharif A SabeMark BroadwinChristopher StoneCynthia XuJiayu HuMeghamsh KanuparthyM Ruhul AbidFrank W SellkePublished in: Biomedicines (2024)
In our swine model of chronic myocardial ischemia, CAN therapy alters several proteins involved in critical molecular pathways, including redox regulation and metabolism. These findings provide additional mechanistic insights into the cardioprotective effects of canagliflozin.